A team led by Munich-based M&A partner Boris Dürr advised Celenus SE, a subsidiary of publicly listed Orpea S.A., on the acquisition of a majority stake in Inoges group. The company's founder Wolfgang K. Hoever will stay on after Orpea's entry as a new majority shareholder and continue to advance the company’s expansion.
Inoges group is a leader in outpatient rehabilitation in Germany and also operates two inpatient rehabilitation facilities. The group further focuses on outsourcing for hospitals, the management of integrated care contracts, rehabilitation sports, and services for occupational health management. More than 1,000 employees at sites managed a volume of 5.2 million patient appointments in 2016, generating revenue of some EUR 50 million. Inoges group’s regional focus lies on North Rhine-Westphalia, Hesse, and Bavaria.
Paris-based publicly listed Orpea is a leading European nursing and rehabilitation operator with some 800 healthcare facilities and over 82,000 beds across Europe. In 2016, Orpea's generated revenue of about EUR 2.5 billion.
Celenus SE is a member of Orpea group and is headquartered in Offenburg. It operates 17 rehabilitation clinics in Germany with about 3,000 beds and two outpatient day centers, making it one of Germany’s largest private operators of rehabilitation facilities. Celenus' specialist treatment offering includes both post-acute aftercare with specializations, particularly in orthopedics, oncology, cardiology, and neurology, as well as the treatment of psychiatric illnesses such as depression and eating disorders.
The acquisition of the majority stake in Inoges group is subject to approval by the antitrust authorities and is expected to be closed in January 2018.
On the part of Heuking Kühn Lüer Wojtek, the transaction was led by Munich-based M&A partners Boris Dürr and Dr. Oliver Treptow. The team led by Boris Dürr has been advising Celenus group on acquisitions and clinic takeovers for many years.